Newsroom | 48740 results

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present new data at ASH on how comprehensive genomic profiling supports diagnosis and treatment decisions in myeloid malignancies....

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced the presentation of initial open-label extension (OLE) data from the company’s ongoing Phase 3 ARGUS trial investigating EPX-100 (clemizole hydrochloride) for the treatment of Dravet syndrome (DS), which showed clinically meaningful reductions in seizure activity in participants with DS along with a favorable benefit-risk profile. The data from poster #3.353 will be presented at the Americ...

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, reaffirms its position as the leader in chronic lymphocytic leukemia (CLL) innovation by showcasing the depth, quality, and momentum of its hematology portfolio at the 67th ASH Annual Meeting and Exposition in Orlando, Florida. The totality of BeOne’s ASH data reinforce BRUKINSA® (zanubrutinib) as the foundational Bruton’s tyrosine kinase inhibitor (BTKi) of choice. “At...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced its entry into a definitive agreement to acquire Bluejay Therapeutics, a privately held biotechnology company focused on viral and liver diseases. The transaction would add worldwide rights to brelovitug, a late-stage, fully human monoclonal antibody with Breakthrough Therapy and PRIME designations for chronic hepatitis delta virus (HDV) to Mirum’s portfolio of rare...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome VT-1953 P2 results...

NEW HAVEN, Conn.--(BUSINESS WIRE)--BioCT, the CT life sciences trade organization, and Shipman & Goodwin LLP, one of Connecticut’s largest law firms, are pleased to announce that Reid Waldman, M.D., has received the Entrepreneur of the Year Award. Dr. Waldman serves as Chief Executive Officer of Veradermics, a late clinical-stage biopharmaceutical company developing potentially first-in-class therapeutics for common dermatologic conditions, including pattern hair loss. This award, establish...

SYDNEY & BOSTON--(BUSINESS WIRE)--AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced it has received the first delivery of high-activity 228Th, the parent isotope of 212Pb and a key starting material to produce the alpha-emitter 212Pb, used to manufacture ADVC001, the company’s lead asset, and other 212Pb-based radioligand therapies in the pipeline. This delivery marks a major milestone for the company and underscor...

SAN FRANCISCO--(BUSINESS WIRE)--Epicrispr Biotechnologies to Present at 44th Annual J.P. Morgan Healthcare Conference...

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, announced the presentation at the American Epilepsy Society (AES) meeting of preliminary 18-month safety and effectiveness results from its ongoing NAUTILUS1 trial evaluating the RNS® System as an adjunctive therapy for the treatment of antiseizure medication (ASM) resistant idiopathic generalized epilepsy (IGE) with generalized tonic...

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of the leading AI foundation model for cancer and the immune system, today announced seven abstracts have been accepted for presentation at the San Antonio Breast Cancer Symposium (SABCS) 2025, taking place from December 9–12, 2025, in San Antonio, Texas. The research, conducted in collaboration with leading cancer centers, demonstrates the power of the BostonGene platform to uncover complex breast cancer tumor biology and drive informed, p...